Over a five-month period, using data from patients in whom alkaline phosphatase (ALP) isoenzyme studies were requested routinely, we compared actual clinical diagnoses with the predicted diagnoses based on the results of electrophoretic separation of ALP isoenzymes on cellulose acetate before and after heat treatment and on elevated enzymatic activity of gamma glutamyl transferase (GGT) and alanine aminotransferase (ALT) activity. ALP isoenzymes were interpreted on a qualitative basis (presence or absence of liver, bone, or other isoenzyme) by individual clinical pathologists. Overall, the consistency of agreement in 61 patients was 66% for GGT, 51% for ALP isoenzymes, and 21% for ALT. In 44 patients with definite diagnoses, the sensitivity and specificity, respectively, of each laboratory test for patients with liver disease were 88 ± 5.7% and 64 ± 14.5% (ALP isoenzymes); 88 ± 5.7% and 91 ± 8.6% (GGT); and 6 ±4.1% and 91 ± 8.6% (ALT). In patients with bone disease, the sensitivity and specificity of ALP isoenzymes was 75 ± 10.8% and 86 ± 6.6%, respectively. The results indicate that isoenzymes as currently performed need to be improved through standardization of the interpretation of ALP isoenzyme patterns to establish uniformity of comments. (Key words: Liver, bone, liver and bone disease, GGT, ALT, Subjective laboratory test) Am J Clin Pathol 1983; 80: 682-685 FOR THE PAST FOUR YEARS, the Clinical Chemistry Laboratory, Charity Hospital, New Orleans, Louisiana, has been offering on a routine basis the electrophoretic separation of alkaline phosphatase (E.C. 3.1.3.1, orthophosphoric acid monoester phosphohydrolase; ALP) isoenzymes. About 25-30 requests for ALP isoenzymes are received monthly. This relatively small number of ALP isoenzyme requests for a 1,000-bed teaching hospital suggested to us that this test may be underused clinically. Theoretically, a laboratory determination that could separate the bone and liver isoenzymes of ALP would answer the question of the source of an increased ALP activity, but to date, laboratory studies regarding the clinical usefulness of ALP isoenzymes have been inconclusive. '-3 -713 Therefore, we decided to review, for a specified time, all patients in whom ALP isoenzymes were requested in an attempt to assess the clinical usefulness of this proReceived November 16, 1982; received revised manuscript and accepted for publication May 23, 1983. Dr. Lum's present address: The Veterans Administration Medical Center, 1400 VFW Parkway, West Roxbury, Massachusetts 02132, and Harvard Medical School, Boston, Massachusetts.
cedure. In addition, we decided to measure gamma-glutamyl transferase (E.C. 2.3.2.1., (glutamyl)-peptide:amino acid glutamyltransferase; GGT) and alanine aminotransferase (E.C. 2.6.2.2, L-alanine-2oxoglutarate aminotransferase; ALT) enzymatic activities, to compare the performance of these two readily available and well-established liver enzymes with the electrophoretic separation of ALP isoenzymes.
Materials
ALP electrophoresis was done twice a week, on Wednesday and Friday. After measurement of total serum ALP activity, electrophoretic separation was performed; specimens received on Wednesday and Friday were processed on that day. Samples received on days other than those designated were frozen at -20°C, until they could be thawed and analyzed on the established twice-weekly schedule. After electrophoresis, samples were refrozen quickly at -20°C and analyzed later for gamma glutamyl transferase and alanine aminotransferase activities within 90 days. All biochemical analyses were done over a period of 25 weeks.
Total alkaline phosphatase activity was determined according to the procedure of Morgenstern and associates, 10 as adapted to use of the Gemsaec centrifugal analyzer.* The sample size was 20 fiL, and the substrate reagent, pnitrophenyl-phosphate, was obtained from Technicon Instrument Corporation, Tarrytown, New York 10591). The reaction was carried out at 30°C, and enzyme activity was converted to U/L at 37°C.
Gamma glutamyl transferase (GGT) activity was measured by the method of Szasz, 12 as adapted for the centrifugal analyzer using "FastChem -y-GT" kit from BioDynamics.f The test was done on the Gemsaec centrifugal analyzer with 20-^L serum sample, at 30°C, and GGT activity was converted to U/L at 37°C.
Serum alanine aminotransferase (ALT) activity was measured by a method:): based on the procedure of Wroblewski and LaDue 14 and Henry and co-workers 6 in a Cen-683 trifichem 400 § using 25 /uL of serum at 30°C and Spin Chem Alt reagent, specifically made to yield a single premixed reagent. The enzyme activity was converted to U/L at 37°C. Alkaline phosphatase isoenzymes were separated by electrophoresis on cellulose acetate membranes with an electrophoresis system supplied by Helena Laboratories, Beaumont, Texas 77704. The separation procedure followed the method of Fritsche and Adams-Park. 5 A 0.5-ml portion of the serum of each specimen was transferred to a stoppered glass test tube, and the tube was placed in a temperature-controlled water bath set at 56 ± 1 °C for 10 minutes. The exactly timed heat treatment was terminated by quickly removing the tube from the water bath and rapidly cooling it in ice water. The serum sample and its heat-treated counterpart were applied to the cellulose acetate on separate channels for electrophoresis. The following markers were used on each cellulose acetate membrane as controls and as guides for the interpretation of ALP isoenzyme patterns: a commercial control containing the liver and intestinal isoenzyme (Helena Laboratories); a placental control from a pregnant patient in the third trimester; and a bone marker from a patient with Paget's disease. These controls were not subjected to the same heat treatment as the patient samples.
ALP isoenzyme patterns were read on a biweekly schedule by a board-certified pathologist. No attempt was made to quantitate individual isoenzymes, nor were there any attempts to standardize the qualitative statements of each pathologist concerning the presence, absence, or the relative amount of each isoenzyme. Acceptance or rejection of individual isoenzyme patterns was based on the appropriate migration and presence of known ALP isoenzyme markers.
Method
To evaluate the correlation between individual laboratory test and the actual clinical diagnosis, we adopted the following protocol. Based on the results of each laboratory test, we initially assigned patients to one of several disease categories. Total ALP activity was first determined on all patient samples. The cut-off point for the definition of an elevated ALP activity-ALP > 100 U/L-was based on previous studies of healthy hospitalized patients free of liver and bone disease. Using our current ALP electrophoretic procedure without modification in the method or in the interpretation of this test, we assigned patients to one of the following diagnostic categories, provided that the total ALP activity was elevated:
Presence of liver isoenzyme = liver disease Presence of bone isoenzyme = bone disease Presence of liver and bone isoenzyme = coexisting liver and bone disease § Union Carbide Corporation, Pleasantville, New York 10570.
Presence of intestinal, placental or atypical isoenzyme = presence of other pathologic process
If the total ALP activity was in the normal range, the patient was not assigned to a disease category and was considered normal. For GGT and ALT, we modified somewhat the disease classification to reflect the inability of these two enzymes to differentiate between liver and bone disease; therefore, no separate category for coexisting liver and bone disease was established. The selection of a cut-off point for the definition of an elevated GGT and ALT was based on previous studies of healthy hospitalized patients at Charity Hospital clinically free of liver disease.
> 40 U/L The following categories were established for assigning patients to disease categories on the basis of GGT and ALT activities:
Elevated GGT or = liver disease Elevated ALT Normal GGT or Normal ALT, = Absence of liver disease, probElevated ALP able bone disease
We selected a period of five months (April to August 1981) for this study. During this period, we reviewed the ALP isoenzyme information for all patients in whom this test was requested, and in addition measured GGT and ALT on the same samples. After assigning patients to the various disease categories, we then set out to determine the degree of clinical-pathologic correlation by reviewing patient charts. ALP isoenzymes were requested in a total of 75 patients during the period studied. Twelve charts could not be located, and in three patients the total ALP activity was normal. The study population consisted of a total of 61 patients, all of whom had elevated ALP activity.
Patient charts were reviewed initially by one clinical pathologist and assigned to one of the following clinical categories without knowledge of total ALP, ALP isoenzymes, GGT, or ALT: (1) liver disease; (2) bone disease; (3) coexisting liver and bone disease; and (4) other. The following criteria were established for assigning patients to the category of liver or bone disease: liver diseaseliver biopsy, laparotomy, postoperative state, history of alcoholism, biochemical evidence of liver disease (increased bilirubin, increased liver enzymes such as AST), hepatoxic drugs, congestive heart failure, septicemia; bone disease-total body bone scan, x-ray evidence of bone disease, bone biopsy, prolonged immobilization (paraplegia), osteomyelitis.
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After individual chart review, three clinical pathologists met jointly and reviewed all patient charts to reach a consensus in assigning each case to a disease category. This was done without knowledge of the laboratory tests being assessed.
The following categories were established for evaluating the degree of consistency or inconsistency between the predicted disease category based on the laboratory test alone and the clinical diagnosis. (1 Table 1 compares the predicted disease category based on each laboratory test and the actual disease category based on clinical information obtained from chart review. The discrepancy between the predicted and actual clinical diagnosis in each category represents 17 patients in whom there was insufficient or no clinical information to assign the case to one of the established categories. Table 2 shows the results for the performance of each laboratory test based on consistency and inconsistency between the predicted and actual clinical diagnosis. ALT was the laboratory test least likely to predict the correct diagnostic category (31/61,51%), followed by ALP isoenzymes (13/ 61, 21%) and GGT (4/61, 6%) inconsistencies. Patients falling into the probable and possible consistency categories had either no diagnosis or insufficient data for disease classification.
Results
The inconsistencies between the predicted and actual clinical categories can be seen more easily in Table 3 . For the purpose of assessing the performance of each laboratory test in patients with liver or bone disease, we eliminated data from 17 patients without definite clinical diagnosis of either disease process. This procedure yielded 44 patients. ALP isoenzymes sometimes indicated the presence of a isoenzyme that did not correlate with the clinical situation (i.e., bone isoenzyme present in patients in liver disease only) or the absence of the isoenzyme in the indicated clinical disease category (i.e., the absence of bone isoenzyme in patients with bone disease). GGT was comparable in sensitivity to ALP isoenzymes in patients with liver disease, was normal in all patients with bone disease, and was normal in only one patient with coexisting bone and liver disease. ALT showed the least number elevated in liver disease (2/28), was abnormal in one patient with bone disease, and was abnormal in one patient with coexisting liver and bone disease.
To estimate the sensitivity and specificity of each laboratory test for either liver or bone disease, we used a 2 X 2 matrix in the 44 patients with definite diagnoses. The performance of ALP isoenzymes in patients with liver and/or liver and bone disease was determined on the basis of the following data:
ALP isoenzymes
Liver 
685
The sensitivity and specificity of ALP isoenzymes for patients with liver disease was 29/33 = 88 ± 5.7% (the standard error of the proportion) and 7/11 = 64 ± 14.5%, respectively.
For the assessment of GGT in patients with liver disease, the following data were analyzed: The sensitivity and specificity of GGT for patients with liver disease were 29/33 = 88 ± 5.7% and 10/11 = 9 1 ± 8.6%, respectively. The performance of ALT in patients with liver disease was assessed using the following matrix: The sensitivity and specificity of ALT with liver disease were 2/33 = 6 ± 4.1% and 10/11 = 9 1 ± 8.6%, respectively. The sensitivity and specificity of ALP isoenzymes in patients with bone disease were 12/16 = 75 ± 10.8% and 24/28 = 86 ± 6.6%, respectively.
GGT
ALT
Discussion
This study raises questions regarding the usefulness of ALP isoenzymes as it is interpreted currently in our laboratory. Despite the incorporation of the heat inactivation step into the ALP procedure to better delineate the liver isoenzyme that is only partially heat-labile, 4 the ALP procedure as currently performed did not result in consistent agreement between the clinical disease and the presence of the appropriate liver or bone isoenzyme.
A major problem with our current ALP isoenzyme test is the lack of uniformity in the interpretation of this subjective procedure. We have no way of knowing whether there was any consistency in the reading of individual ALP isoenzyme patterns by a number of different clinical pathologists (up to four) because no effort was made to standardize the interpretive comments of each pathologist observer before this study was undertaken. One recent study showed considerable intrapathologist variation in the interpretation of ALP isoenzyme patterns of a pooled human serum control. 9 GGT, combined with total ALP activity, performed reasonably well as an indicator in patients with hepatobiliary disease. Our work confirms the findings of others who found GGT to be more sensitive than ALT as an indicator of liver disease. 8 
-''
Most ALP isoenzyme requests were on patients with increased total ALP activity (61/64 or 95%). In most cases, however, the isoenzyme findings did not lead to significant changes in diagnosis or treatment. For example, in four of the eleven patients with bone disease who also showed the presence of liver isoenzyme, the result was ignored and no further workup for hepatic disease was done.
This study points out the usefulness of this type of retrospective study for the evaluation of laboratory tests that are routinely in use and that have been assumed to be of clinical usefulness.
